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Abstract: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) represent an
unlimited source of human CMs that could be a standard tool in drug research. However, there is
concern whether hiPSC-CMs express all cardiac ion channels at physiological level and whether they
might express non-cardiac ion channels. In a control hiPSC line, we found large, “noisy” outward
K+ currents, when we measured outward potassium currents in isolated hiPSC-CMs. Currents
were sensitive to iberiotoxin, the selective blocker of big conductance Ca2+-activated K+ current
(IBK,Ca). Seven of 16 individual differentiation batches showed a strong initial repolarization in
the action potentials (AP) recorded from engineered heart tissue (EHT) followed by very early
afterdepolarizations, sometimes even with consecutive oscillations. Iberiotoxin stopped oscillations
and normalized AP shape, but had no effect in other EHTs without oscillations or in human left
ventricular tissue (LV). Expression levels of the alpha-subunit (KCa1.1) of the BKCa correlated with
the presence of oscillations in hiPSC-CMs and was not detectable in LV. Taken together, individual
batches of hiPSC-CMs can express sarcolemmal ion channels that are otherwise not found in the
human heart, resulting in oscillating afterdepolarizations in the AP. HiPSC-CMs should be screened
for expression of non-cardiac ion channels before being applied to drug research.
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1. Introduction
Human induced pluripotent stem-cell derived cardiomyocytes (hiPSC-CMs) have gained interest as
a human model to study heart physiology and pathophysiology [1–4], cardiovascular pharmacology [5]
and cardiac repair [6]. In this context, it is important that hiPSC-CMs share properties of human
adult CMs. Many reports claimed that characteristics of hiPSC-CMs might differ from adult CMs, a
finding frequently interpreted as immaturity. On the one hand, immaturity could be caused by the lack
of cardiac ion channels or by differences in expression levels such as the inward rectifier potassium
current (IK1) [7–10]. On the other hand, hiPSC-CMs can show ion currents, which are absent in adult
human CMs such as the T-type calcium current [11,12]. Based on these findings, there is a need for a
detailed electrophysiological characterization of hiPSC-CMs before using them as a model for human
CMs. Here we report the coincidently found expression of a non-cardiac ion channel in hiPSC-CMs
as a peculiarity of a single control cell line: the big conductance calcium activated potassium current
(BKCa; alternatively used names: Maxi-K, slo1, KCa1.1).
BKCa is a voltage- and calcium-gated potassium channel (KCa1.1) generating huge conductivity
for potassium. BKCa is widely expressed in the human body, mainly in neural cells, blood vessels,
kidney, but not in in cardiomyocytes. Recently, artificial expression of BKCa was shown to be able to
shorten action potentials (APs) in murine CMs [13]. Consequently, expression of the non-cardiac BKCa
current in human CMs was proposed as a genetic therapy for the long QT syndrome. However, the
contribution of individual ion channels to repolarization and resulting AP shape differs from murine
to human CMs. Putative impact of BKCa to human cardiac electrophysiology remains unclear.
The goal of this study was to draw attention to the fact that hiPSC-CMs can express non-cardiac
ion channels. In addition, we had the chance to elucidate how the expression of BKCa may influence
the membrane potential of human CMs. Based on our findings, we propose a regular assessment for
expression of non-cardiac ion channels as a part of quality control when using hiPSC-CMs.
2. Methods
2.1. Generation of hiPSC and Engineered Heart Tissue (EHT)
The hiPSC line C25 (kind gift from Alessandra Moretti, Munich, Germany) was reprogrammed by
lentivirus [1] and was expanded in FTDA medium and differentiated in a three step protocol based on
growth factors and a small molecule Wnt inhibitor DS07 (kind gift from Dennis Schade, Dortmund,
Germany) as previously published [14–16]. The hiPSC line ERC018 were generated in-house from
skin fibroblasts of a healthy subject using the CytoTuneTM-iPS Sendai Reprogramming Kit (Thermo
Fisher Scientific, Waltham, MA, USA) and differentiated to cardiomyocytes as described for C25.
In brief, confluent undifferentiated cells were dissociated (0.5 mM EDTA; 10 min) and cultivated in
spinner flasks (30 × 106 cells/100 mL; 40 rpm) for embryoid body formation overnight. Mesodermal
differentiation was initiated in embryoid bodies over three days in suspension culture with growth
factors (BMP-4 (R&D Systems, 314-BP), activin-A (R&D Systems, 338-AC) and FGF2 (PeproTech,
100-18B)). Cardiac differentiation was performed either in adhesion or in suspension culture with
Wnt-inhibitor DS07. Cells were cultured in a humidified temperature and gas-controlled incubator
(37 ◦C, 5% CO2, 5% O2 and 21% O2 for final cardiac differentiation). At day 14 the spontaneously
beating hiPSC-CMs were dissociated with collagenase II (Worthington, LS004176; 200 U/mL, 3.5 h).
For quality control, dissociated cells were analyzed by flow cytometry as described before [14,17] with
anti-cardiac troponin T-FITC (Miltenyi, clone REA400, 130-112-756). All differentiation runs utilized for
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this study had 64–96% cardiac Troponin T positive cells (Supplementary Materials Figure S2). Further
characterization of the non-CMs within the EHT was evaluated previously by our group [6], showing
low expression of vimentin-positive fibroblast-like markers and the virtual absence of endothelial,
neuronal, and endodermal markers. ICell and iCell2 cardiomyocytes are commercially available
hiPSC-CM lines purchased from Fujifilm Cellular Dynamics (Madison, Wisconsin, USA) and were
included in expression analysis after culture in EHT. For three-dimensional culture EHTs were generated
with 1 × 106 hiPSC-CM/100 µL EHT mastermix as previously described [18]. EHTs were cultured in a 37
◦C, 7% CO2 and 40% O2 humidified cell culture incubator with a medium consisting of DMEM (F0415,
Biochrom; Berlin, Germany), 10% heat-inactivated horse serum (Gibco 26050, Thermo Fisher Scientific,
Waltham, MA, USA), 1% penicillin/streptomycin (Gibco 15140), insulin (10 µg/mL; Sigma-Aldrich
I9278, St. Louis, MO, USA) and aprotinin (33 µg/mL; Sigma-Aldrich A1153). EHTs were cultured for at
least 3 weeks to allow maturation. The work with hiPSC was approved by the Ethical Committee of
the University Medical Center Hamburg-Eppendorf (Az. PV4798, 28.10.2014). All donors gave written
informed consent.
2.2. Human Adult Heart Tissue
This investigation conforms to all principles outlined by the Declaration of Helsinki and the
Medical Association of Hamburg. All materials from patients were taken with informed consent of the
donors. Left ventricular free wall and left ventricular septum samples were obtained from patients
undergoing heart transplantation or from aortic valve surgery.
2.3. Current Recordings
HiPSC-CMs in EHT were isolated with collagenase II for 5 h (200 U/mL, Worthington, LS004176
dissolved in HBSS-Puffer without Mg2+ or Ca2+, Gibco 14175-053 and 1 mM HEPES; pH 7,4), and
re-plated on gelatin-coated coverslips for 24–48 h in order to maintain adherence under perfusion.
Outward K+ currents were measured at 37 ◦C, using the whole-cell configuration of the patch clamp
technique. Axopatch 200B amplifier (Axon Instruments, Foster City, CA, USA) and ISO2 software
were used for data acquisition and analysis (MFK, Niedernhausen, Germany). Heat-polished pipettes
were pulled from borosilicate filamented glass (Hilgenberg, Malsfeld, Germany). Tip resistances were
2.5–5 MΩ when filled with pipette solution. Seal resistances were 2–4 GΩ. The cells were investigated
in a small perfusion chamber placed on the stage of an inverse microscope. Application of drugs was
performed by a system for rapid solution changes (Cell Micro Controls, Virginia Beach, VA, USA;
ALA Scientific Instruments, Long Island, NY, USA) [19]. The experiments were performed with the
following bath solution (in mM): NaCl 120, KCl 5.4, HEPES 10, CaCl2 2, MgCl2 1 and glucose 10 (pH 7.4,
adjusted with NaOH). Outward currents were elicited by 1000 ms depolarizing test pulses from −80 to
+70 mV (0.2 Hz). The pipette solution included (in mM): DL-Aspartate potassium salt 80, KCl 40, NaCl
8, HEPES 10, Mg-ATP 5, Tris-GTP 0.1, EGTA 5 and CaCl2 4.4, pH 7.4, adjusted with KOH [20].
2.4. AP Recordings
To record APs in intact EHT and in left ventricular trabeculae we used sharp microelectrodes as
reported previously [5,9,21]. Microelectrode tip resistances were 20–50 MΩ when filled with 3 mM
KCl. APs were elicited by field stimulation at 1 Hz, 0.5 ms stimulus duration and 50% above threshold
intensity. The following bath solution was used (in mM): NaCl 125, KCl 5.4, MgCl2 0.6, CaCl2 1,
NaH2PO4 0.4, NaH2CO3 22 and glucose 5.5 and was equilibrated with O2–CO2 (95:5). The experiments
were performed at 37 ◦C.
2.5. Molecular Biology
Total RNA was extracted from snap frozen LV and EHT using an RNAeasy mini Kit (Qiagen,
Valencia, CA, USA). RNA concentration was determined per fluorometric quantitation with QubitTM
(Thermo Fisher Scientific; Waltham, MA, USA) according to the manufacturer’s instructions. Of total
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RNA 50 ng was used for expression analysis by nanoString nCounter® SPRINT Profiler according
to the manufacturer’s instructions. Raw data were analyzed with nSolverTM Data Analysis Software
including background subtraction using negative controls and normalization to two housekeeping
genes (GAPDH and PGK1).
2.6. Mathematical Modelling and Computer Simulations
To simulate the BKCa current in silico, we extended a previously published formulation [22]
to include (1) calcium dependence according to the Lin et al. [23] data, and (2) inactivation kinetics
according to Ding et al. [24] data. To demonstrate the contribution of BKCa current on AP repolarization,
we integrated the BKCa model to a well-established human left ventricular CM model [25].
2.7. Statistical Analysis
Results are presented as mean values ± SEM. Area under the curve was calculated by using the
GraphPad Prism Software 5.02 (GraphPad Software, San Diego, CA, USA). Statistical differences were
evaluated by using the Student’s t-test (paired or unpaired) or repeated measures ANOVA, followed by
a Bonferroni test, where appropriate. A value of p < 0.05 was considered to be statistically significant.
2.8. Drugs
All drugs and chemicals were obtained from Sigma-Aldrich (St. Louis, MI, USA) except for
iberiotoxin (IBTX, Tocris Bioscience, Bristol, UK).
3. Results
3.1. Outward Potassium Currents in hiPSC-CMs, Appearance of IBK,Ca
Large, transient outward currents were elicited in hiPSC-CMs (Figure 1A) by depolarizing test
pulses. We found in several C25-hiPSC-CMs a large, inactivating outward current followed by a late
sustained current with an irregular shape during the entire depolarizing test pulse. The irregular-shaped
“noisy” currents were similar to BKCa currents, which were reported previously in mesenchymal stem
cells [26]. Similar to that report we used rather high test pulse potentials (+70 mV) from physiological
resting membrane potential of −80 mV and increased the free Ca2+ concentration of the pipette solution
from 2 to 4.4 mM to facilitate the detection of BKCa [26]. The selective IBK,Ca blocker IBTX (100 nM) was
used to identify the IBK,Ca (Figure 1A). Of the hiPSC-CMs 76% (19 out of 25) showed IBTX-sensitive
outward currents suggesting the presence of BKCa; the area under the curve was reduced by IBTX from
30.6 ± 5.1 pAs/pF to 20.2 ± 4.1 pAs/pF (n = 19, p < 0.0001, paired t test, Figure 1B). IBTX inhibited both
the peak and late current density (peak from 82.9 ± 11.5 pA/pF to 44.8 ± 7.6 pA/pF, p < 0.0001, Figure 1C
and late: from 29.2 ± 5.4 pA/pF to 17.8 ± 3.4 pA/pF; n = 19, p = 0.004, Figure 1D). In IBTX-insensitive
hiPSC-CMs, baseline values of outward peak and late currents were smaller compared to IBTX-sensitive
hiPSC-CMs. Furthermore, in hiPSC-CMs without the irregular-shaped outward current IBTX did not
change peak or late currents (peak: 45.4 ± 6.4 pA/pF baseline vs. 43.4 ± 3.9 pA/pF IBTX, p = 0.594, n = 6
and late: 8.3 ± 2.6 pA/pF baseline vs. 7.5 ± 1.8 pA/pF IBTX, n = 6, p = 0.363; paired t test). HiPS-CMs
from the commercially available iCell cell line did not show irregular-shaped “noisy” currents or
IBTX-sensitivity (Supplementary Materials Figure S1).
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(C) and current at the end of the test pulse (late current, D). Mean values ± SEM. * p < 0.05, unpaired 
Student’s t test for basal values in insensitive vs. sensitive hiPSC-CMs; ## p < 0.01, ### p < 0.001; paired 
Student’s t test for basal vs. IBTX; n = number of isolated cells/number of individual differentiation 
batches. 
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3.2. Action Potentials with Strong Initial Repolarization and Oscillations Are Sensitive to Iberiotoxin
APs recorded in C25-EHTs, exhibiting the IBTX-sensitive irregular- haped outward current,
showed a pronounced initial repolarization (“notch”) below the later plateau level of the AP and
the initial notch was followed by a (very) early afterdepolarization (Figure 2). In some APs the
notch was followed by a peculiar oscillation during plateau phase of the AP. This peculiarity of
notch/oscillation was only observed in some of independent differentiation batches of the C25 cell line,
but never in any other of three in-house cell lines or five commercial cell lines investigated with sharp
microelectrodes as previously described [5,9,27–30]. When the notch/oscillation was detected in one
EHT, all impalements showed this peculiarity including all EHTs from this differentiation batch. From
all C25 batches investigated with sharp microelectrode, we detected seven with notch/oscillations and
11 without. The passage number of individual differentiation batches was not significantly different
with or without notch/oscillations (77.1 ± 5.9, n = 7 vs. 67.9 ± 7.9, n = 9; p = 0.391) as well as the
hiPSC-CM differentiation efficiency (81% ± 5% vs. 85% ± 3% TnT + cells, p = 0.51). In addition,
spontaneous beating frequency was not different between EHTs with or without notch/oscillations
(1.09 ± 0.19 Hz, n = 9 vs. 0.92 ± 0.07 Hz; n = 14; p = 0.34). EHTs were treated with 300 nM ivabradine
to allow pacing at 1 Hz as previously described [5]. Under these conditions, APD90 was slightly longer
in EHTs with notch/oscillations than without (279 ± 12 ms, n = 18/9/6 vs. 226 ± 6 ms, n = 30/17/9;
p = 0.0044). Take-off potential, upstroke velocity and AP amplitude were not significantly different.
The number of oscillations within one AP varied between 1 and 6. In case of several oscillations, there
was a rather constant cycle length of oscillations in different EHTs (22.8 ± 0.9 ms, n = 11). In case of
multiple oscillations, the amplitude decreased with each subsequent oscillation (ranging from 50 to
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10 mV, Figure 2B). We used the specific inhibitor IBTX (100 nM) in order to evaluate whether oscillations
originate from IBK,Ca. To quantify effects of IBTX on early repolarization we analyzed the membrane
potential when the initial repolarization reached its lowest point (on average 9.2 ± 0.7 ms after AP
upstroke).
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Figure 2. Pronounced notch with oscillation in the plateau phase of action potential (AP) recorded
from engineered heart tissue (EHT) derived by C25 human induced pluripotent stem cell-derived
cardiomyocytes (hiPSC-CMs). (A) Original AP recordings without (A) and with (B) notch followed
by oscillating afterdepolarizations in EHT from cell line C25. (C) Summary of the results for take-off
potential (TOP), AP amplitude (APA), maximum upstroke velocity (Vmax), AP duration at 90%
repolarization (APD90), ** p < 0.01, unpaired Student’s t test; n = number of impalements/number of
EHTs/number of individual differentiation batches.
In case of notch/oscillations, IBTX (100 nM) lifted the membrane potential at this time point from
−43.5 ± 5.6 to −13.2 ± 8.3 mV (n = 7, p = 0.001, paired t-test). APD10, APD20, APD50 and APD70
but not APD90 was significantly prolonged by IBTX (Figure 3). IBTX did not affect AP duration in
EHTs without notch/oscillations. In addition, IBTX did not show any effect on AP in human LV tissue
(Figure 3).
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Figure 3. Effects of iberiotoxin (IBTX) on action potentials (APs) in C25 engineered heart tissue (EHT)
and in human left ventricular tissue (LV). Original AP recordings before and after exposure to IBTX
(100 nM, green) in EHTs with (A) and without (B) notch/oscillations from cell line C25 and in LV (C).
Mean values of AP duration at different levels of repolarization (APD10-90) before and after exposure to
IBTX (100 nM) in EHTs with (D) and without (E) notch in cell line C25 and in LV (F). Mean values ± SEM,
* p < 0.05, ** p < 0.01, paired Student’s t test.
3.3. EHT with Notch/Oscillations in the AP Showed Large BKCa Expression
The BKCa channel is formed as a tetramer of the channel fo ming alpha-subunit KCa1.1 encoded
by the KCNMA1 gene. We performed retrospectively expression analysis in order to investigate
whether there was an association between appearance of oscillations and the expression level of
KCNMA1. The mRNA level for the channel forming alpha-subunit KCa1.1 showed very low expression
in human LV tissue. The same holds true for the in-house control cell line ERC018 and the commercially
available cell lines iCell and iCell2, where notch or oscillations in the AP have never been detected [5].
In contrast, all EHTs from C25 from which we could record notch/oscillations showed a substantial
increase in KCNMA1 mRNA, which is encoding for KCa1.1 (Figure 4). In addition, RNA sequencing
showed a 12-fold higher expression level for KCNMA1 in C25 than in the control cell line ERC001
(Supplementary Figure S4). Other genes related to KCNMA1 did not show major alterations in
expression. Immunofluorescence analysis of hiPSC-CMs revealed the expression of the alpha-1 subunit
of the BKCa channel in the C25 cell line with enhanced signal intensity at cell-cell contacts, whereas no
signal was detected in the control cell line [30] (Supplementary Figure S5).
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potassium channel. Individual expr ssion levels of in left ventri ular tissue (LV) and
engineered heart tissue (EHT) from cell line C25 (with ut and with notch/oscillations), ERC018, iCell
and iCell2. Mean values ± S M, *** p < 0.001, 1-way ANOVA with multiple comparison, n = number of
patients for LV and n = number of EHT/number of individual differentiation batches.
3.4. Computer Simulations Corroborate the Effect of the Non-Cardiac BKCa to Human AP
To eval ate the impact of BKCa on repolarization quantitatively, we integrated a BKCa model into
a human ventricular CM model. Simulation results in Figure 5 demonstrated that a reasonably sized
BKCa current can cause a deep notch in the AP. The dynamics of the notch (Figure 5A) match the kinetics
of the simulated BKCa current (Figure 5B). Although inclusion of BKCa did not cause oscillations of the
membrane voltage similar to in vitro observations, the deep notch enhanced drastically L-type Ca2+
current (ICa,L, Figure 5C).
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BKCa current (B) causes a de p notch in the action potential (A), and a substantial increase in the
amplitude of L-type Ca2+ c rrent ( ).
4. Discussion
The main findings of this study were:
(1) i s could express ion channels otherwise not foun in adult cardiomyocytes.
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(2) In human adult ventricular myocardium, BKCa did not contribute to AP shape.
(3) In hiPSC-CMs BKCa could induce irregular AP shapes with oscillations resembling very early
after depolarizations.
BKCa channels are widely expressed in various cell types, including electrically excitable and
non-excitable cells [31]. Due to the Ca2+-sensitivity, they provide relevant negative feedback mechanism
in the regulation of intracellular Ca2+ elevation and membrane potential [32]. Almost every cell type
expresses BKCa in the inner mitochondrial membrane (BKmito) [33]. In CMs, pharmacological opening
of BKmito reduces ischemia reperfusion injury [34]. Sarcolemmal expression of BKCa is typically
found in vascular smooth muscle cells, regulating myogenic tone and thereby blood flow. In CMs
from rodents and cardiac tissue from humans, sarcolemmal expression of BKCa is very low or almost
non-existent [35–37]. Here we confirm low expression levels of BKCa in human LV myocardium.
Among CMs from other species, IBTX sensitive currents were found only in cultured embryonal chicken
CMs [38]. Contribution to repolarization in this species is unclear. In rat ventricular myocardium, IBTX
does not affect AP shape [39]. Here, we demonstrated for the first time that human ventricular APs
were insensitive to IBTX. In consequence, the detection of IBK,Ca in C25-hiPSC-CMs during patch clamp
recordings was unexpected and surprising, since BKCa is not known to be expressed in the sarcolemma.
The effectivity of the selective blocker of IBK,Ca [26,40], IBTX, which only binds from the external
side of the channel [41], confirmed the hypothesis that a non-cardiac channel is present and active at
transmembrane level in the hiPSC-CMs. These findings were also confirmed by expression analysis
in which the existence of the notch/oscillation in the AP correlated with the high expression levels of
KCNMA1, encoding for the alpha-subunit (KCa1.1) of the BKCa. In contrast, KCNMA1 expression was
low in human LV tissue and correspondingly IBTX did not show any effect on APs from human LV,
which to our knowledge has not been described before.
Recently, overexpression of non-cardiac BKCa in CMs was proposed as a treatment for LQTS [13],
since BKCa is a hyperpolarizing channel, which might shorten human AP. Support for this idea came
from a study describing the electrophysiological function of BKCa in HL-1 cells by viral overexpression,
a cell line derived from a murine atrial tumor. BKCa overexpression reduced the very short AP of this
murine model by 50% (APD90 from 30 to 14 ms) and was proposed as a potential genetic therapy to
reduce AP duration (APD) of the LQT syndrome [13]. In contrast to the experiments in HL-1 cells, we
observed that in hiPSC-CMs, the presence of BKCa induces oscillations in the early plateau phase and
no speed-up in the final repolarization [13].
The pronounced initial repolarization could be confirmed by the in-silico integration of the IBK,Ca
in modeling ventricular myocyte AP (Figure 5). However, the inclusion of BKCa could not resemble
oscillations of the membrane voltage. Nevertheless, we would expect that oscillation might be induced
by an alternating feedback mechanism [32] of the IBK,Ca and the L-type Ca2+ current (ICa,L), since the
deep notch drastically enhanced L-type Ca2+ current (Figure 5C). The afterdepolarizations following
the initial repolarization might be also due to activation of ICa,T [11] or the sodium calcium exchanger,
however, the exact mechanism remains unclear. More accurate and detailed mathematical modeling
would require in vitro data on spatial distribution and localization of the BKCa and Ca2+ channels,
which is beyond the scope of this study.
Afterdepolarizations might complicate the evaluation of how the BKCa affects APD. In vitro, there
was a slightly longer APD90 when BKCa was present, which could be confirmed in silico. However,
the inhibition of IBK,Ca by iberiotoxin in AP with notch/oscillations did not significantly alter APD90,
averaged values tended even to longer APD90. The apparent differential contribution of BKCa to the
APD revealed at baseline level or by pharmacological intervention might be due to remodeling of other
ion channels downstream to BK expression or due to potential off-target effects of iberiotoxin. Taken
together, our results do not support the idea that BKCa overexpression can cure LQTS in humans, since
BKCa might lead to afterdepolarization and arrhythmia.
Previously, it was shown that the IBK,Ca current contribute to outward currents in the murine
sinoatrial node and the selective blocker paxilline decreased beating rate by more than 50% [42].
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However, the exact role of IBK,Ca in pacemaking is widely unclear, since substantial decrease in diastolic
depolarization by paxilline does not fit to very small contribution of BKCa to total potassium outward
currents activated at positive membrane potentials. Nevertheless, spontaneous beating is a peculiarity
of hiPSC-CMs and the autonomic activity of hiPSC-CMs is not fully understood. Therefore, it seems
reasonable to speculate that BKCa may be involved in pacemaking of hiPSC-CMs. However, we would
not expect a large impact of IBK,Ca to pacemaking in EHT, since beating rate in EHT with and without
expressing BKCa did not differ.
The reason for the unexpected expression of BKCa in individual differentiation batches of a single
hiPSC-CM cell line (C25) is very difficult to evaluate retrospectively. Cell line C25 did not show
chromosomal anomalies at passage number 40 and 92 (Supplementary Figure S3). Since 6 out of 7
individual differentiation batches were done from lower passage numbers than 92, it seems that BK
expression was not the consequence of karyotype abnormalities. As notch/oscillation were observed
also in preparations with very high differentiation efficiencies (90% and 93%) and hiPSC-CM fraction
in EHT was even enriched in comparison to 2D culture (Supplementary Materials Figure S2B), we
are confident that BK expression is not due to an extraordinary high fraction of non-cardiac cells
within the EHT. Strong batch effects, as either all or none of the EHTs from one preparation depicted
signs of BKCa expression, argue for an upregulation of BKCa due to events occurring during stem cell
culture and cardiac differentiation. There are two factors that might have raised the likelihood for
spontaneous mutations in the stem-cell culture. The C25 cell line was reprogrammed by lentivirus
and it was passaged to very high number (up to 107 passages). To avoid these factors, we changed
to Sendai virus and restricted passage number for future experiments. Since KCNMA1 related genes
did not show major alterations in contrast to KCNMA1 itself, we would account a genetic alteration
more likely than an upregulation due to regulatory pathways. In addition, various reports show
that iPS-cells frequently acquire genetic alterations in cell culture. Kilpinen et al. [43] showed that
chromosome 10, harboring BKCa/KCNMA1, was among the most susceptible loci to copy number
alterations. In addition, in a study searching for variants that provide mutated cells with a growth
advantage in culture, KCNMA1 candidate mosaic variants were identified in two independent hES cell
lines [44]. Thus, a genetic alteration leading to a reoccurring overgrowth of BK misexpressing hiPSC is
the most likely explanation for our finding. Regulatory expression profiling might reveal this change
of BKCa activity in advance.
5. Conclusions
Our results clearly demonstrated that hiPSC-CMs could possess even non-cardiac ion channels
affecting AP waveform causing afterdepolarizations and oscillations in the AP. This might serve as an
example that iPS cell culture could lead to genetic alterations with functional consequences. Therefore,
we felt that cell culture and differentiation protocols should be standardized as much as possible and
that expression of non-cardiac sarcolemmal ion channels should be considered before hiPSC-CMs are
used for pharmacological studies. Screening for the expression of the KCNMA1 gene might be one
potential quality parameter.
6. Limitations
We are aware that the description of the BKCa in a single control cell line of hiPSC-CMs is of limited
transferability, especially since we could not uncover conditions or mechanisms of the unexpected
BKCa expression. Nevertheless, presence of BKCa is a good example that hiPSC-CMs can express
non-cardiac proteins with a huge impact on physiological parameters. Although IBTX has been
described as selective for IBK,Ca [41], non-specific effects of IBTX cannot be completely excluded. LV
tissue was obtained from patients with heart disease; a potential difference to healthy LV tissue is
unclear. We implemented the BK in the previously developed hiPSC-CM model [5], but we failed to
induce notch/oscillations in that model. Obviously, our present model does not reflect the cellular
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ultrastructure at the level of detail that would be required for simulating the putative close proximity
of the BK and CaL channels.
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AP Action potential
APD Action potential duration
APD90 Action potential duration at 90% repolarization
BKCa Big conductance calcium activated potassium channel, (Maxi-K, slo1, KCa1.1)
CM Cardiomyocytes
EAD Early afterdepolarization
EHT Engineered heart tissue
hiPSC-CMs Human induced pluripotent stem cell-derived cardiomyocytes
IBTX Iberiotoxin
IBK,Ca Big-conductance calcium activated potassium current
ICa,L L-type calcium current
LV Left ventricle
RMP Resting membrane potential
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